Literature DB >> 9156957

Amlodipine: an overview of its pharmacodynamic and pharmacokinetic properties.

P A van Zwieten1.   

Abstract

Amlodipine, a third-generation dihydropyridine calcium antagonist, has a mode of action and pharmacodynamic profile which are comparable to those of conventional compounds in this series, such as nifedipine. Its physicochemical behavior, however, appears to be somewhat different. A pKa value of 8.7 means that amlodipine is predominantly present in the ionized form at a physiologic pH. It possesses, therefore, a strong affinity for cell membranes. These phenomena apparently contribute to amlodipine's unique pharmacokinetic profile, which is characterized by almost complete absorption, late-peak plasma concentrations, high bioavailability, and slow hepatic biodegradation. This profile translates into potential clinical benefits by virtue of a slow onset of action and long duration of effect. The slow onset of action may explain why there seems to be very little reflex tachycardia and a lower incidence of vasodilator side effects when comparing amlodipine with conventional dihydropyridines. The slow elimination of amlodipine explains the long duration of action, which allows a convenient once-daily dosage schedule.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 9156957

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  5 in total

1.  Enzyme linked immunosorbent assay for determination of amlodipine in plasma.

Authors:  K Matalka; T El-Thaher; M Saleem; T Arafat; A Jehanli; A Badwan
Journal:  J Clin Lab Anal       Date:  2001       Impact factor: 2.352

Review 2.  Angiotensin Receptor Blocker and Calcium Channel Blocker Preventing Atrial Fibrillation Recurrence in Patients with Hypertension and Atrial Fibrillation: A Meta-analysis.

Authors:  Haotian Ma; Hongcheng Jiang; Jing Feng; Yong Gan
Journal:  Cardiovasc Ther       Date:  2021-05-17       Impact factor: 3.023

3.  Fixed-dose combination orally disintegrating tablets to treat cardiovascular disease: formulation, in vitro characterization and physiologically based pharmacokinetic modeling to assess bioavailability.

Authors:  Thomas J Dennison; Julian C Smith; Raj K Badhan; Afzal R Mohammed
Journal:  Drug Des Devel Ther       Date:  2017-03-16       Impact factor: 4.162

4.  Impact of Food and Drink Administration Vehicles on Paediatric Formulation Performance Part 2: Dissolution of Montelukast Sodium and Mesalazine Formulations.

Authors:  J Martir; T Flanagan; J Mann; Nikoletta Fotaki
Journal:  AAPS PharmSciTech       Date:  2020-10-15       Impact factor: 3.246

5.  Extemporaneous Compounding and Physiological Modeling of Amlodipine/Valsartan Suspension.

Authors:  Wafa' J Aabed; Asma H Radwan; Abdel Naser Zaid; Naser Y Shraim
Journal:  Int J Hypertens       Date:  2021-03-12       Impact factor: 2.420

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.